KromaTiD, Inc. provides products and services for genetic disease research to scientists worldwide. The Company’s patented chromosome imaging platform provides disease researchers with the ability to detect all types of DNA rearrangements including previously undetectable classes of mutations. These discoveries are likely to lead to development of new clinical diagnostics....
KromaTiD, Inc. provides products and services for genetic disease research to scientists worldwide. The Company’s patented chromosome imaging platform provides disease researchers with the ability to detect all types of DNA rearrangements including previously undetectable classes of mutations. These discoveries are likely to lead to development of new clinical diagnostics.
More information

Investors

Recommendations

Peter Adams

I would like to recommend KromaTiD and their team. I have been working with them since 2012 and have been impressed with the traction that they have gained during that time. They have developed IP that can be monetized in a number of ways and their current strategy of building libraries of test kits that can be sold is highly scalable and would make this company an attractive target for M&A at some time in the near future.

I have been very impressed with Christopher Tompkins and now with the addition of Alex Vodenlich as CEO, the company has a team that is worthy of funding and can execute on their plan. KromaTiD pitched with RVC recently and has several investors who are following the deal currently.

terry opgenorth CSO at VetDC

KromaTiD has issued patents that give it a clear competitive advantage for product development and commercialization of the next generation of chromosome imaging - direction genomic hybridization or dGH, and enables discovery of disease-causing mutations that no other technology, including sequencing, can easily identify. These research reagents also may be turned into diagnostic products. KromaTiD has products on market and satisfied customers, very strong and supportive Scientific Advisory Board, and exceptional management. There are clearly identified acquirers of the technology. I've been close to the company for the last 6 years, and believe it is now investor ready. That belief turned into a personal investment in the current offering. In my various roles within the bioscience industry, there are few emerging technology companies among the many I see that I also consider investable for angels. This is one of only three I've invested my own money in over the past 8 years.